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Recent studies have linked changes in peripheral chemokine concentrations to the pres-
ence of both addictive behaviors and psychiatric disorders. The present study further 
explore this link by analyzing the potential association of psychiatry comorbidity with 
alterations in the concentrations of circulating plasma chemokine in patients of both sexes 
diagnosed with alcohol use disorders (AUD). To this end, 85 abstinent subjects with AUD 
from an outpatient setting and 55 healthy subjects were evaluated for substance and 
mental disorders. Plasma samples were obtained to quantify chemokine concentrations 
[C–C motif (CC), C–X–C motif (CXC), and C–X3–C motif (CX3C) chemokines]. Abstinent 
AUD patients displayed a high prevalence of comorbid mental disorders (72%) and 
other substance use disorders (45%). Plasma concentrations of chemokines CXCL12/
stromal cell-derived factor-1 (p < 0.001) and CX3CL1/fractalkine (p < 0.05) were lower 
in AUD patients compared to controls, whereas CCL11/eotaxin-1 concentrations were 
strongly decreased in female AUD patients (p < 0.001). In the alcohol group, CXCL8 
concentrations were increased in patients with liver and pancreas diseases and there 
was a significant correlation to aspartate transaminase (r = +0.456, p <  0.001) and 
gamma-glutamyltransferase (r = +0.647, p < 0.001). Focusing on comorbid psychiatric 
disorders, we distinguish between patients with additional mental disorders (N =  61) 
Abbreviations: ALT/GPT, alanine transaminase; AST/GOT, aspartate transaminase; AUD, alcohol use disorders; CCL11/
eotaxin-1, chemokine (C–C motif) ligand 11/eotaxin-1; CCL2/MCP-1, chemokine (C–C motif) ligand 2/monocyte chemo-
tactic protein-1; CCL3/MIP-1α, chemokine (C–C motif) ligand 3/macrophage inflammatory protein-1 alpha; CXCL8/IL-8, 
chemokine (C–X–C motif) ligand 8/interleukin-8; CXCL12/SDF-1, chemokine (C–X–C motif) ligand 12/stromal cell-derived 
factor-1; CX3CL1/fractalkine, chemokine (C–X3–C motif) ligand 1/fractalkine; DSM-IV-TR, Diagnostic and Statistical Manual 
of Mental Disorders-4th Edition-Text Revision; GGT, gamma-glutamyltransferase; PRISM, Psychiatric Research Interview for 
Substance and Mental Diseases.
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and other substance use disorders (N = 38). Only CCL11 concentrations were found 
to be altered in AUD patients diagnosed with mental disorders (p < 0.01) with a strong 
main effect of sex. Thus, patients with mood disorders (N = 42) and/or anxiety (N = 16) 
had lower CCL11 concentrations than non-comorbid patients being more evident in 
women. The alcohol-induced alterations in circulating chemokines were also explored in 
preclinical models of alcohol use with male Wistar rats. Rats exposed to repeated eth-
anol (3 g/kg, gavage) had lower CXCL12 (p < 0.01) concentrations and higher CCL11 
concentrations (p <  0.001) relative to vehicle-treated rats. Additionally, the increased 
CCL11 concentrations in rats exposed to ethanol were enhanced by the prior exposure 
to restraint stress (p < 0.01). Concordantly, acute ethanol exposure induced changes in 
CXCL12, CX3CL1, and CCL11 in the same direction to repeated exposure. These results 
clearly indicate a contribution of specific chemokines to the phenotype of AUD and a 
strong effect of sex, revealing a link of CCL11 to alcohol and anxiety/stress.
Keywords: chemokine, alcohol use disorder, psychiatric comorbidity, outpatient setting, PrisM, eotaxin, sex
inTrODUcTiOn
Substantial evidence suggests that the immune system modu-
lates behaviors through specific actions of inflammatory signals 
in the central nervous system (CNS) (1). Among these signals, 
chemokines are chemoattractants involved in cellular migra-
tion and intercellular communication (2), which are known to 
regulate neuronal development, survival, and regeneration in 
the CNS (3). Chemokines might reach the brain through the 
blood compartment, but also they can be released by neurons 
and glial cells in response to physiological or pathological 
conditions. In particular, the resident immune cells (micro-
glia) have a prominent role in the mediation of chemokine 
actions. They have been reported to be involved in synaptic 
remodeling, an essential step in behavioral consolidation and 
acquisition. Moreover, chemokine receptors expressed by 
microglia contribute to brain development, especially during 
critical developmental periods, controlling essential processes 
such as synaptic pruning (4, 5). Consequently, dysregulation 
in the chemokine signaling and neuroinflammation have been 
proposed to contribute to cognitive dysfunctions and mental 
diseases (1).
Additionally, alterations in circulating chemokines {e.g., 
chemokine C–C motif ligand 2 [CCL2, also referred to monocyte 
chemoattractant protein-1 (MCP-1)], chemokine C–C motif 
ligand 11 [CCL11, eotaxin-1], chemokine C–X–C motif ligand 
8 [CXCL8, interleukin-8 (IL-8)], and chemokine C–X–C motif 
ligand 12 [CXCL12, stromal cell-derived factor-1 (SDF-1)]} 
have been recently associated with psychiatric disorders such 
as cocaine use disorders (6), mood disorders (7, 8), generalized 
anxiety (9), personality disorders (9), and Alzheimer’s disease 
(10). Collectively, these findings suggest that these inflammatory 
signals could be considered as pathologically relevant biomarkers 
or therapeutic targets for psychopathologies (11).
Concerning substance use disorders, a growing literature 
indicates that the pharmacodynamic actions of alcohol and 
other drugs of abuse involve the central activation of immune 
signaling (12). Thus, studies in rodents have revealed that 
drug-induced alterations in chemokines, such as CXCL12 and 
CCL2, promote common addictive behaviors in a brain region-
specific manner (2, 13–15). Additional studies in alcoholics 
have reported activated microglia and increased concentrations 
of CCL2 and other inflammatory molecules in multiple brain 
regions (3, 16). These elevated CCL2 concentrations have also 
been detected in the cerebrospinal fluid of alcoholics, correlat-
ing with plasma concentrations of liver transaminases (17). 
Chemokines and their receptors are known for their role in liver 
injury, especially the CC chemokine family in animal models 
(18), and both alcoholic hepatitis and cirrhosis are associated 
with distinct patterns of chemokine expression such as CCL8, 
CCL2, chemokine C-C motif ligand 3 [CCL3, also referred to 
macrophage inflammatory protein-1 alpha (MIP-1α)], and 
chemokine C-C motif ligand 4 (CCL4, macrophage inflamma-
tory protein-1 beta) (19).
These findings confirm the existence of a close interaction 
between inflammatory signals from peripheral tissues (e.g., 
liver) and neuroinflammation through the blood stream and 
the blood–brain barrier (20). In line with these observations, we 
reported recently that plasma levels of CXCL12 and chemokine 
C–X3–C motif ligand 1 (CX3CL1, also referred to fractalkine) are 
correlated to cocaine symptom severity, which allows stratify-
ing the cocaine addicts in patients with different incidence of 
comorbid psychiatric disorders (6, 21). However, in the case of 
alcohol use disorders (AUD), plasma chemokines have been 
evaluated almost exclusively in the context of alcoholic hepatitis 
(18, 22). Taking into account all these observations, it is feasible 
to hypothesize that the chronic use of drugs of abuse leads to 
progressive changes in the neurobiology and behavior that might 
be mediated not only by the innate immune system, but also 
by the coordinated actions of chemokines. The impact of these 
chemokine-mediated responses in the brain might contribute to 
the addicted phenotype and to the high prevalence of psycho-
pathologies observed in addicts (3).
In the present study, we tested the hypothesis that lifetime 
AUD are associated with altered circulating chemokine concen-
trations that could be observed during abstinence in male and 
Table 1 | baseline sociodemographic characteristics in abstinent 
alcohol use disorders patients and controls.
Variable group
alcohol 
(N = 85)
control 
(N = 55)
p-Value
Age [mean (SD)] Years 47.16 (7.27) 45.20 (9.97) 0.211a
BMI [mean (SD)] kg/m2 25.69 (3.86) 24.82 (3.38) 0.177a
Sex [N (%)] Women 27 (31.8) 21 (38.2) 0.469b
Men 58 (68.2) 34 (61.8)
Marital status  
[N (%)]
Single 28 (32.9) 26 (47.3) 0.012b
Married/cohabiting 27 (31.8) 22 (40.0)
Divorced/separated/
widowed
30 (35.3) 7 (12.7)
Education  
[N (%)]
≤Primary/
elementary
24 (28.2) 10 (18.2) 0.227b
≥Secondary 61 (71.8) 45 (81.8)
Occupation  
[N (%)]
Employed 47 (55.3) 42 (76.4) 0.012b
Unemployed 38 (44.7) 13 (23.6)
Psychological/
psychiatric 
support [N (%)]
No 0 (0.0) 52 (94.5) <0.001b
Yes 85 (100) 3 (5.5)
BMI, body mass index.
Bold numbers denote significant differences (p < 0.05).
ap-Value from Student’s t-test.
bp-Value from Fisher’s exact test or chi-square test.
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female patients. Furthermore, variables associated with alcohol 
addiction (i.e., abstinence, liver and/or pancreas diseases, and 
criteria for AUD) and psychiatric comorbidity (other substance 
use disorders and mental disorders) could be associated with 
alterations in the expression of certain chemokines in the plasma 
of patients with AUD in outpatient treatment. Additional studies 
in rats were performed to test the impact of alcohol administra-
tion on the chemokine expression, exploring also the combined 
association of stress and alcohol exposure.
MaTerials anD MeThODs
Participants and recruitment
The present cross-sectional study was performed in a total of 140 
White Caucasian subjects who were divided into alcohol and con-
trol groups. Eighty-five abstinent subjects diagnosed with AUD 
(alcohol abuse or dependence) were recruited from outpatient 
programs for alcohol use disorder at Hospital Universitario 12 de 
Octubre in Madrid (Spain) for a period of 18 months (November 
2013–May 2015). Fifty-five healthy individuals with no history 
of substance use disorders or pathological use of substances 
were matched with the alcohol group for age, sex ratio, and body 
mass index (BMI). The average participant was a man (65%) of 
46.6 years and a BMI of 25.5 kg/m2.
The participants in the alcohol group had to meet eligibil-
ity criteria based on (A) inclusion criteria: age ≥18 years up to 
60 years of age, lifetime AUD, and at least 4 weeks of abstinence 
before testing; (B) exclusion criteria: presence of infectious dis-
eases, incapacitating cognitive alterations to complete psychiatric 
interviews, and pregnancy for female participants. A breathalyzer 
was used daily for estimating blood alcohol content from a breath 
sample. Because of high incidence of alcohol-induced diseases 
in accessory organs (liver and pancreas), we included these 
individuals in the alcohol group. A description of the sample is 
presented in Table 1.
Alcohol use disorder patients were being treated with 
pharmacological approaches and psychosocial techniques. 
Sixty-one subjects were treated with disulfiram during the last 
year. Regarding psychiatric medication, 60 patients were treated 
with psychiatric medication during the last year: antidepressants 
(N =  35), anxiolytics (N =  26), anticonvulsants (N =  29), and 
antipsychotics (N = 7).
ethics statement
Written informed consent was obtained from each participant 
after a complete description of the study and discussing any 
question or issue. The study and protocols for recruitment were 
approved by the Ethics Committee of the CEI Provincial de 
Málaga and Hospital Universitario 12 de Octubre in accordance 
with the “Ethical Principles for Medical Research Involving 
Human Subjects” adopted in the Declaration of Helsinki by 
the World Medical Association (64th WMA General Assembly, 
Fortaleza, Brazil, October 2013), Recommendation No. R (97) 
5 of the Committee of Ministers to Member States on the 
Protection of Medical Data (1997), and Spanish data protection 
act (Ley Orgánica 15/1999 de Protección de Datos, LOPD).
clinical assessments
Patients from outpatient programs for alcohol use disorder 
were evaluated according to “Diagnostic and Statistical Manual 
of Mental Disorders-4th Edition-Text Revision” (DSM-IV-TR) 
criteria, using the Spanish version of the “Psychiatric Research 
Interview for Substance and Mental Diseases” (PRISM) (23). 
Diagnoses were made using two time-frames: “current” (criteria 
were met within the past year) and “past” (criteria were met 
before the previous 12 months). Lifetime prevalence, taking into 
accounts both current and past diagnoses, was used to present the 
frequency of substance use disorders and other mental disorders. 
DSM-IV-TR criteria for substance dependence and abuse were 
used to diagnose substance use disorders and determine the 
severity of substance use disorders (6, 24).
Control subjects were initially evaluated by PRISM (for sub-
stance screening and abuse and dependence) and subsequently by 
the Spanish version of the “Composite International Diagnostic 
Interview” (CIDI) to detect psychiatric disorders (25). All the 
interviews were performed by experienced psychologists who 
had received both PRISM and CIDI training.
collection of Plasma samples
Blood samples were obtained in the morning (9:00–11:00 a.m.) 
after fasting for 8–12 h (previous to the psychiatric interviews). 
Venous blood was extracted into 10  mL K2-EDTA tubes (BD, 
Franklin Lakes, NJ, USA) and was immediately processed to 
obtain plasma. Blood samples were centrifuged at 2,200 × g for 
15  min (4°C) and individually assayed for detecting infectious 
diseases by three rapid tests for HIV (HIVTOP®), hepatitis B 
(HBVTOP®), and hepatitis C (HCVTOP®) purchased from ALL.
4García-Marchena et al. Chemokines and Alcohol
Frontiers in Psychiatry | www.frontiersin.org January 2017 | Volume 7 | Article 214
DIAG (Strasbourg Cedex, France). Samples displaying infection 
were discarded following safety protocols. Plasma samples were 
individually characterized, registered, and stored at −80°C until 
further analyses.
Multiplex immunoassays
Chemokines were chosen based on previous studies about 
inflammatory mediators and psychiatric disorders and 
addiction (6). A Bio-Plex Suspension Array System 200 
(Bio-Rad Laboratories, Hercules, CA, USA) was used to 
quantify chemokine concentrations in plasma with a Procarta 
Immunoassay Kit using polystyrene beads and an appropriate 
diluent Plasma Standard Diluent Kit (Affymetrix-Panomics, 
Santa Clara, CA, USA). This method of analysis is based on the 
Luminex technology and a human chemokine 6-plex panel was 
used to simultaneously detect the following analytes: CXCL8 
(IL-8), CXCL12 (SDF-1), CX3CL1 (fractalkine), CCL2 (MCP-
1), CCL3 (MIP-1α), and CCL11 (eotaxin-1). The measurements 
of these analytes in plasma were performed following the 
manufacturer’s instructions (6). Raw data were analyzed using 
the Bio-Plex Manager Software 4.1 (Bio-Rad Laboratories, 
Hercules, CA, USA). Data are expressed as picograms of protein 
per milliliter of plasma.
Determination of biochemical  
Parameters related to hepatic  
and Pancreatic Functions
In addition to immunoassays, plasma samples of the participants 
were assessed for markers of hepatic and pancreatic functions in a 
clinical analysis laboratory (Analisis Clinicos Rodriguez Vergara 
S.L., Malaga, Spain). We examined the following parameters: 
aspartate transaminase (AST/GOT), alanine transaminase (ALT/
GPT), gamma-glutamyltransferase (GGT), pancreatic α-amylase, 
and pancreatic lipase. The reference ranges from the labora-
tory were established as follows: 0–40, 0–40, 0–45, 5–100, and 
0–67 IU/L, respectively.
animals and ethics statements
Animal studies were conducted on 5- to 8-week-old male Wistar 
rats (Charles River Laboratories España S.A., Barcelona, Spain) 
weighing 200–250  g at the beginning of the experiments. Rats 
were kept in clear plastic cages under a 12-h light/dark cycle 
(lights off at 8:00 p.m.) in a room at ambient temperature (23°C) 
and humidity (55%) in the Animal Resource Center at the 
University of Málaga (Spain). Unless otherwise indicated, water 
and chow pellets were available ad libitum throughout the course 
of these studies.
Experiments and procedures were conducted under strict 
adherence to the European Directive 2010/63/EU on the protec-
tion of animals used for scientific purposes and with Spanish 
regulations (RD 53/2013 and 178/2004). All efforts were made to 
minimize unnecessary suffering. All protocols were approved by 
the Committee on the Ethics of Universidad de Málaga (CEUMA, 
7-2016-A).
experimental Procedures
For ethanol experiments, rats were accustomed to the experimen-
tal conditions including handling and intragastric gavage (i.g.) 
procedure for a period of 1  week using saline. The number of 
animals for each experimental group was ranged 7–8.
Repeated Ethanol Exposure
Rats were gavaged daily with a solution of ethanol (3 g/kg in saline) 
or saline as vehicle during 4 weeks. An additional group of rats 
were individually restrained for a period of 90 min in a Plexiglas 
cylindrical restrainer (diameter ×  length: 6  cm ×  20  cm) with 
breathing holes in a separate testing room 48 h before beginning 
the ethanol or saline i.g. treatment. All rats were sacrificed by 
decapitation 1 week after the last ethanol or saline i.g. session in 
a room provided with low-intensity white noise.
Acute Ethanol Exposure
Another set of rats were acutely treated with a solution of 
ethanol (3  g/kg in saline, i.g.) and returned to the home cages 
immediately. Rats were sacrificed by decapitation at 30, 60, 120, 
and 240 min after the ethanol administration in a room provided 
with low-intensity white noise. To evaluate the effect of time on 
chemokine expression, two groups of naive rats were sacrificed 
at the beginning (t = 0 min) and at the end (t = 240 min) of the 
experiment with no ethanol exposure.
immunoassay analyses
Blood samples from the ethanol experiments in rats were immedi-
ately collected and centrifuged (2,000 × g for 15 min) and plasmas 
were kept at −80°C for immunoassay analyses. CXCL12 (SDF-1), 
CX3CL1 (fractalkine), and CCL11 (eotaxin-1) were measured 
in rat plasma with commercial enzyme-linked immunosorbent 
assay (ELISA) kits in 96-well plate format following the manufac-
turer’s instructions: ELISA Kit for SDF-1 (product #: SEA122Ra; 
Cloud-Clone Corp., Wuhan, Hubei, PR China), Rat Fractalkine 
ELISA Kit (CX3CL1) (product #: ab100760; Abcam, Cambridge, 
UK), and Rat Eotaxin 1 (Eotaxin 1/CCL11/ECF) ELISA Kit 
(product #: CSB-E07319r; Cusabio, College Park, MD, USA). The 
plates were read at 450 nm within 30 min at a set wavelength of 
540 nm or 570 nm. Data are expressed as nanograms of protein 
per milliliter of plasma.
statistical analyses
All clinical data in the tables are expressed as number and per-
centage of subjects [N (%)] or mean and SD of concentrations 
[mean (SD)]. The significance of differences in categorical and 
normal continuous variables was determined using Fisher’s exact 
test (chi-square test) and Student’s t-test, respectively.
Statistical analysis of chemokine concentrations was per-
formed using multiple analysis of covariance (ANCOVA) to 
indicate the relative effect of explanatory variables and their 
interactions on the chemokine expression in the plasma, 
controlling for additional covariates. Log(10)-transformation 
was used to ensure statistical assumptions for positive skewed 
distributions. The post  hoc comparisons in ANCOVA were 
performed using Sidak’s correction test. Estimated marginal 
FigUre 1 | Plasma chemokine concentrations in abstinent alcohol use disorders (aUD) patients and control subjects. (a) CXCL8 [interleukin-8 (IL-8)]; 
(b) CXCL12 [stromal cell-derived factor-1 (SDF-1)]; (c) CX3CL1 (fractalkine); (D) CCL2 [monocyte chemoattractant protein-1 (MCP-1)]; (e) CCL3 [macrophage 
inflammatory protein-1 alpha (MIP-1α)]; and (F) CCL11 (eotaxin-1) concentrations according to “history of AUD.” Bars are estimated marginal means and 95% 
confidence intervals (95% CI) (picograms per milliliter). Data were analyzed by two-way analysis of covariance (ANCOVA) and *p < 0.05 and ***p < 0.001 denote a 
significant main effect of “history of AUD.” (g) CCL3 (MIP-1α) and (h) CCL11 (eotaxin-1) concentrations according to “history of AUD” and “sex.” Bars are marginal 
means and 95% CI (picograms per milliliter). Data were analyzed by two-way ANCOVA and *p < 0.05 denotes a significant main effect of “sex.” +++p < 0.001 
denotes significant differences compared to male AUD patients because there was an interaction of factors.
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means [95% confidence intervals (95% CI)] of chemokine 
concentrations were expressed and represented in the figures 
after back-transformation if that was the case. In addition, cor-
relation analyses were performed using the Pearson’s coefficient 
(r). Regarding data from rat studies, Student’s t-test and analysis 
of variance (ANOVA) with multiple post  hoc tests (Dunnett 
and Tukey tests) were conducted for statistical analyses and 
chemokine concentrations in rat plasma are expressed as mean 
and SEM.
A p-value  <  0.05 was considered statistically significant. 
Statistical analyses were performed using the GraphPad Prism 
version 5.04 software (GraphPad Software, San Diego, CA, USA) 
and IBM SPSS Statistical version 22 software (IBM, Armonk, NY, 
USA).
resUlTs
Plasma chemokine concentrations in 
abstinent aUD Patients and controls
The impact of lifetime diagnosis of AUD on the plasma levels of 
chemokines in men and women was investigated using a two-way 
ANCOVA with “history of AUD” and “sex” (N =  92 men and 
N =  48 women) as factors, and “age” and “BMI” as covariates. 
Concentrations were examined to ensure that statistical assump-
tions were met and a base-10 logarithmic transformation of 
chemokine concentrations was conducted for CXCL8, CXCL12, 
CX3CL1, CCL2, and CCL3. Estimated marginal means for “his-
tory of AUD” were represented after back-transformation in 
Figure 1.
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Plasma concentrations of CXC chemokines (i.e., CXCL8 
and CXCL12) were differentially affected. Thus, although 
plasma CXCL8 concentrations were not affected by “history 
of AUD” (Figure 1A), we observed a main effect of this fac-
tor on CXCL12 concentrations [F(1,129) =  11.589, p <  0.001] 
(Figure 1B). Consequently, a significant reduction in plasma 
CXCL12 concentrations was detected in the alcohol group 
compared to the control group [285.76 (95% CI =  266.07–
307.61) pg/mL and 349.95 (95% CI = 319.15–384.59) pg/mL, 
respectively].
CX3CL1 had an expression profile similar to that observed 
for CXCL12. Therefore, plasma CX3CL1 concentrations were 
also significantly affected by “history of AUD” [F(1,129) =  6.124, 
p = 0.015] (Figure 1C) and a significant decrease in the plasma 
concentrations was also observed in the alcohol group compared 
to the control group [4.592 (95% CI = 4.140–5.105) pg/mL and 
5.689 (95% CI = 4.966–6.516) pg/mL, respectively].
Regarding the CC chemokine expression (i.e., CCL2, CCL3, 
and CCL11), plasma concentrations were not affected by “his-
tory of AUD” as observed in the Figures  1D–F. However, the 
statistical analysis revealed a main effect of “sex” on CCL3 
concentrations [F(1,129) =  6.679, p =  0.011] (Figure  1G) and a 
significant interaction between “history of AUD” and “sex” on 
CCL11 concentrations [F(1,129) = 4.922, p = 0.028] (Figure 1H). 
Plasma CCL3 concentrations were higher in women than men 
with no distinction between both alcohol and control groups. 
In the case of CCL11, paired comparisons revealed that CCL11 
concentrations were decreased in female compared to male 
subjects but only in the alcohol group (p < 0.001). Furthermore, 
the “age” was significantly related to CCL11 concentrations 
[F(1,129) =  14.969, p <  0.001] and correlation analysis indicated 
a positive association between “age” and CCL11 concentrations 
(r = +0.299, p < 0.001) in the total sample. Additional correla-
tion analyses between “age” and CCL11 concentrations were 
conducted in different groups according to each factor (“history 
of AUD” or “sex”) and we observed an enhanced association in 
the control group (r = +0.423, p = 0.002) and in male participants 
(r = +0.384, p = 0.001).
alcohol-related Variables and Plasma 
chemokine concentrations in abstinent 
aUD Patients
We evaluated the relative effects of variables associated with 
AUD and their interactions on chemokine concentrations in 
the alcohol group using a two-way ANCOVA. The independ-
ent variables that we included were as follows: alcohol-induced 
“liver and pancreas diseases” (N =  20 disease and N =  65 no 
disease), “sex” (N = 58 men and N = 27 women), “AUD symp-
tom severity,” length of “abstinence,” and “age.” For all analyses, 
“psychiatric medication” was included as confounding variable. 
All variables were examined to ensure that statistical assump-
tions were met.
“AUD symptom severity,” length of “abstinence,” and “age” 
were fixed at the following mean values: 6.9 (SD = 2.3) criteria for 
AUD, 9.2 (SD = 11.8) months of abstinence, and 47.2 (SD = 7.3) 
years. Plasma concentrations of CXCL12, CX3CL1, CCL3, and 
CCL2 were not affected by any of the variables that were evaluated 
in abstinent AUD patients. However, we found significant effects 
on CXCL8 and CCL11 concentrations.
Liver and Pancreas Diseases and CXCL8 
Concentrations in Abstinent AUD Patients
CXCL8 concentrations were significantly affected by “liver and 
pancreas diseases” [F(1,77) = 11.409, p < 0.001] (Figure 2A) but 
there was a disordinal interaction between “liver and pancreas 
diseases” and “sex” [F(1,77) = 5.773, p = 0.019] (Figure 2B). Thus, 
multiple paired comparisons revealed a significant increase 
in CXCL8 concentrations in women diagnosed with alcohol-
induced diseases (N = 5) compared to female patients with no 
diseases (N = 22) (p < 0.05). In addition, “psychiatric medication” 
was significantly related to CXCL8 concentrations [F(1,77) = 6.500, 
p =  0.013] and patients treated with medication (N =  13 with 
alcohol-induced diseases and N = 47 with no diseases) displayed 
higher CXCL8 concentrations relative to patients with no medi-
cation (N = 7 with alcohol-induced diseases and N = 17 with no 
diseases) during the last year.
Because alcoholic liver and pancreas damage are character-
ized by changes in certain circulating markers we examined 
AST/GOT, ALT/GPT, GGT, pancreatic α-amylase, and pan-
creatic lipase levels in patients and their degree of association 
with chemokine concentrations. We found an overall increase 
of plasma levels of these markers in AUD patients diagnosed 
with cirrhosis, hepatitis, and/or pancreatitis compared to 
AUD patients with no diseases, whereas control subjects had 
lower levels of these circulating markers than AUD patients 
(Table 2). Regarding correlation studies, only CXCL8 concen-
trations were significantly correlated to AST/GOT (r = +0.456, 
p <  0.001) and GGT (r = +0.647, p <  0.001) after multiple 
testing correction with Bonferroni. Although the subclinical 
affectation of the liver and pancreas in AUD patients could 
induce changes in the expression of other chemokines, we 
observed no associations in the total sample (control and 
alcohol group) with the exception of CXCL8 with AST/GOT 
(r = +0.394, p =  0.001) and CXCL8 and GGT (r = +0.563, 
p < 0.001).
Sex Differences and CCL11 Concentrations  
in Abstinent AUD Patients
Regarding CCL11, despite there was no main effect of “liver and 
pancreas diseases” (Figure  2C), concentrations were strongly 
affected by “sex” [F(1,77) =  8.298, p =  0.005] (Figure  2D) with 
no interaction. Estimated means indicated that male abstinent 
patients displayed higher CCL11 concentrations than female 
patients [43.35 (95% CI  =  39.90–46.99) pg/mL and 32.21 
(95% CI  =  27.93–37.07) pg/mL, respectively]. Furthermore, 
we detected a significant effect of “abstinence” [F(1,77) =  4.239, 
p = 0.041] and we found a negative correlation between CCL11 
concentrations and length of abstinence but this association 
failed to reach statistical significance. Similar to previous analysis 
of CCL11 concentrations in the total sample, the “age” was also 
significantly related to CCL11 concentrations [F(1,77)  =  8.891, 
p = 0.004].
FigUre 2 | Plasma concentrations of cXcl8 [interleukin-8 (il-8)] and ccl11 (eotaxin-1) in abstinent alcohol use disorders patients with liver and/or 
pancreas diseases. (a) CXCL8 (IL-8) concentrations according to “liver and pancreas diseases”; (b) CXCL8 (IL-8) concentrations according to “liver and pancreas 
diseases” and “sex”; (c) CCL11 (eotaxin-1) concentrations according to “liver and pancreas diseases”; and (D) CCL11 (eotaxin-1) concentrations according to “liver 
and pancreas diseases” and “sex.” Bars are estimated marginal means and 95% CI (picograms per milliliter). Data were analyzed by two-way analysis of covariance 
and **p < 0.01 and ***p < 0.001 denote significant main effect of “sex” and “liver and pancreas diseases,” respectively. +p < 0.05 denotes significant differences 
compared to female patients with no diseases because there was an interaction of factors.
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Psychiatric comorbidity in  
abstinent aUD Patients
Since chemokines have been linked to psychiatric disorders, we 
studied the high prevalence of psychiatric comorbidity (76%) 
diagnosed in abstinent AUD patients. Thus, the alcohol group 
was divided into comorbid and non-comorbid patients according 
to lifetime diagnosis of substance use disorders (45%) and mental 
disorders (72%) for characterization (Table 3). Additionally, the 
presence of psychiatric comorbidity was also studied in women 
and men considering the potential impact of sex differences on 
psychiatric disorders (Table 4).
Prevalence of Comorbid Substance  
Use Disorders in Abstinent AUD Patients
As is shown in Table 3, abstinent AUD patients diagnosed with 
comorbid substance use disorders [predominantly cocaine (74%) 
and cannabis (40%)] were younger men with low incidence of 
liver and pancreas diseases relative to patients with no additional 
substance use disorders. Interestingly, patients with comorbid 
substance use disorders had a higher prevalence of common 
mental disorders (90%), mainly personality disorders (42%) and 
ADHD (47%), than non-comorbid patients (57%). When patients 
with comorbid substance use disorders were grouped according 
to sex (N = 31 men and N = 7 women) (Table 4), we observed no 
differences relative to sex but there was a trend for female patients 
to use other substances of abuse with no preference and to display 
high prevalence of mood (86%) and personality (71%) disorders.
Prevalence of Comorbid Mental Disorders in 
Abstinent AUD Patients
Regarding patients diagnosed with other comorbid mental dis-
orders [mainly mood disorders (69%)], we found no differences 
Table 3 | baseline sociodemographic variables and psychiatric disorders in abstinent alcohol use disorders patients grouped according to psychiatric 
comorbidity.
Variable alcohol (N = 85)
comorbid substance use disorders Other comorbid mental disorders
no (N = 47) Yes (N = 38) p-Value no (N = 24) Yes (N = 61) p-Value
Age [mean (SD)] Years 48.9 (6.1) 45.1 (8.1) 0.017a 47.8 (6.6) 46.9 (7.6) 0.621a
BMI [mean (SD)] kg/m2 25.8 (3.8) 25.58 (3.9) 0.823a 25.6 (3.6) 25.7 (4.00) 0.835a
Sex [N (%)] Women 20 (42.6) 7 (18.4) 0.021b 6 (0.25) 21 (0.35) 0.450b
Men 27 (57.4) 31 (81.6) 18 (0.75) 40 (0.65)
Liver and pancreas 
diseases [N (%)]
Steatosis 8 (17.0) 1 (2.6) 0.024b 5 (20.8) 4 (6.6) 0.017b
Cirrhosis 5 (10.6) 1 (2.6) 4 (16.7) 2 (3.3)
Pancreatitis 4 (8.5) 1 (2.6) 2 (8.3) 3 (4.9)
Lifetime alcohol use 
disorders  
[N (%)]
Abuse 1 (2.1) 4 (10.5) 0.109b 0 (0.0) 5 (8.2) 0.220b
Dependence 5 (10.6) 1 (2.6) 1 (4.2) 6 (9.8)
Both 41 (87.2) 33 (86.8) 23 (95.8) 50 (82.0)
Smoking [N (%)] No 5 (10.6) 5 (13.2) 0.934b 1 (4.2) 8 (13.1) 0.469b
Yes 34 (72.3) 27 (71.1) 20 (83.3) 45 (73.8)
Former smoker 8 (17.0) 6 (15.8) 3 (12.5) 8 (13.1)
Other lifetime 
substance use 
disorders [N (%)]
No 47 (100.0) 0 (0.0) – 20 (83.3) 27 (44.3) 0.001b
Yes 0 (0.0) 38 (100.0) 4 (16.7) 34 (55.7)
Cocaine 0 (0.0) 28 (73.7) – 3 (12.5) 25 (41.0) 0.020b
Cannabis 0 (0.0) 15 (39.5) – 2 (8.3) 13 (21.3) 0.214b
Heroin 0 (0.0) 3 (7.9) – 0 (0.0) 3 (4.9) 0.555b
Sedatives 0 (0.0) 2 (5.3) – 0 (0.0) 2 (3.3) 1.000b
Others 0 (0.0) 7 (18.4) – 2 (8.3) 5 (8.2) 1.000b
Common lifetime 
mental disorders 
[N (%)]
No 20 (42.6) 4 (10.5) <0.001b 24 (100.0) 0 (0.0) –
Yes 27 (57.4) 34 (89.5) 0 (0.0) 61 (100.0)
Mood 20 (42.5) 22 (57.9) 0.194b 0 (0.0) 42 (68.9) –
Anxiety 7 (14.9) 9 (23.7) 0.404b 0 (0.0) 16 (26.2) –
Psychosis 4 (8.6) 2 (5.3) 0.687b 0 (0.0) 6 (9.8) –
Personality 5 (10.6) 16 (42.1) 0.001b 0 (0.0) 21 (34.4) –
ADHD (childhood) 4 (8.5) 18 (47.4) <0.001b 0 (0.0) 22 (36.1) –
BMI, body mass index; ADHD, attention deficit hyperactivity disorder.
Bold numbers denote significant differences (p < 0.05).
ap-Value from Student’s t-test. Age: t = 2.47, df = 83.
bp-Value from Fisher’s exact test or chi-square test.
Table 2 | estimated marginal means of circulating markers related to liver and pancreas functions in abstinent alcohol use disorders patients and 
controls.
Variable alcohol with diseases 
(N = 20)
alcohol with no 
diseases (N = 65)
control  
(N = 55)
p-Valuea
Aspartate transaminase [mean (SD)] Reference ranges [0.0–40.0] IU/L 46.11 (4.01)+ 29.49 (2.24) 27.94 (3.14) 0.001
Alanine transaminase [mean (SD)] Reference ranges [0.0–40.0] IU/L 49.16 (4.78)++ 32.34 (2.67) 30.00 (3.74) 0.004
Gamma-glutamyltransferase [mean (SD)] Reference ranges [0.0–45.0] IU/L 47.84 (7.18)++ 37.18 (4.00)+++ 19.48 (5.62) 0.005
Pancreatic α-amylase [mean (SD)] Reference ranges [5.0–100.0] IU/L 77.00 (9.16) 69.33 (5.11) 59.84 (7.17) 0.316
Pancreatic lipase [mean (SD)] Reference ranges [0.0–67.0] IU/L 35.42 (3.53) 39.49 (1.97)+++ 29.09 (2.76) 0.011
Underlined numbers denote out of reference ranges (normal ranges).
Bold numbers denote significant differences (p < 0.05).
ap-Value from one-way analysis of variance using F statistic.
+,++,+++Significant differences compared to the control group after a multiple post hoc Dunnett/Tukey test.
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in age and sex compared to patients with no disorders (Table 3). 
However, there was a low incidence of liver and pancreas diseases 
in comorbid patients. In this case, patients with common mental 
disorders displayed a higher prevalence of other substance use 
disorders (56%) than patients with no mental disorders (17%), 
predominately cocaine use disorders (41%). According to sex, 
Table 4 | baseline sociodemographic variables and psychiatric disorders in abstinent alcohol use disorders patients diagnosed with psychiatric 
comorbidity grouped according to sex.
Variable alcohol (N = 85)
comorbid substance use disorders Other comorbid mental disorders
Male (N = 31) Female (N = 7) p-Value Male (N = 40) Female (N = 21) p-Value
Age [mean (SD)] Years 44.7 (8.3) 46.7 (7.7) 0.562a 45.9 (8.3) 48.9 (5.6) 0.148a
BMI [mean (SD)] kg/m2 26.1 (4.0) 23.3 (3.3) 0.090a 26.6 (4.0) 24.0 (3.5) 0.013a
Liver and pancreas 
diseases [N (%)]
No 28 (90.3) 7 (100.0) 1.000b 35 (87.5) 17 (81.0) 0.706b
Yes 3 (9.7) 0 (0.0) 5 (12.5) 4 (19.0)
Steatosis 1 (3.2) 0 (0.0) – 2 (5.0) 2 (9.5) –
Cirrhosis 1 (3.2) 0 (0.0) – 1 (2.5) 1 (4.8) –
Pancreatitis 1 (3.2) 0 (0.0) – 2 (5.0) 1 (4.8) –
Lifetime alcohol use 
disorders [N (%)]
Abuse 3 (9.7) 1 (14.3) 1.000b 3 (7.5) 2 (9.5) 1.000b
Dependence 28 (90.3) 6 (85.7) 37 (92.5) 19 (90.5)
Smoking [N (%)] No 4 (12.9) 1 (14.3) 0.568b 4 (10.0) 4 (19.0) 0.574b
Yes 23 (74.2) 4 (57.1) 31 (77.5) 14 (66.7)
Former smoker 4 (12.9) 2 (28.6) 5 (12.5) 3 (14.3)
Other lifetime substance 
use disorders [N (%)]
No 0 (0.0) 0 (0.0) – 13 (32.5) 14 (66.7) 0.015b
Yes 31 (100.0) 7 (100.0) 27 (67.5) 7 (33.3)
Cocaine 25 (80.6) 3 (42.9) 0.063b 22 (55.0) 3 (14.3) 0.003b
Cannabis 13 (41.9) 2 (28.6) 0.681b 11 (27.5) 2 (9.5) 0.187b
Heroin 1 (3.2) 2 (28.6) 0.081b 1 (2.5) 2 (9.5) 0.270b
Sedatives 1 (3.2) 1 (14.3) 0.339b 1 (2.5) 1 (4.8) 1.000b
Others 7 (3.2) 0 (0.0) 0.309b 5 (12.5) 0 (0.0) 0.154b
Common lifetime mental 
disorders [N (%)]
No 4 (12.9) 0 (0.0) 1.000b 0 (0.0) 0 (0.0) –
Yes 27 (87.1) 7 (100.0) 40 (100.0) 21 (100.0)
Mood 16 (51.6) 6 (85.7) 0.203b 26 (65.0) 16 (76.2) 0.561b
Anxiety 8 (25.8) 1 (14.3) 1.000b 11 (27.5) 5 (23.8) 1.000b
Psychosis 2 (6.5) 0 (0.0) 1.000b 4 (10.0) 2 (9.5) 1.000b
Personality 11 (35.5) 5 (71.4) 0.108b 14 (35.0) 7 (33.3) 1.000b
ADHD (childhood) 17 (54.8) 1 (14.3) 0.093b 19 (47.5) 3 (14.3) 0.012b
BMI, body mass index; ADHD, attention deficit hyperactivity disorder.
Bold numbers denote significant differences (p < 0.05).
ap-Value from Student’s t-test.
bp-Value from Fisher’s exact test or chi-square test.
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patients diagnosed with comorbid mental disorders were bal-
anced between women and men and some differences were found 
(Table  4). Thus, female patients with mental disorders had a 
decreased prevalence of substance use disorders (33%) compared 
to male patients (68%). Although we observed a similar diagnosis 
of mental disorders in women and men lower, there was a low 
prevalence of ADHD in female patients (14%).
Finally, a more precise diagnosis of common mental disorders 
according to sex is shown in Table  5, distinguishing between 
primary and alcohol-induced disorders for mood, anxiety, and 
psychotic disorders.
Psychiatric comorbidity and Plasma 
chemokine concentrations
The impact of psychiatric comorbidity on chemokine expression 
was analyzed using a two-way ANCOVA with the following 
factors: the diagnosis of “comorbid substance use disorders” 
or diagnosis of “comorbid mental disorders” and “sex.” These 
independent variables were controlled for “age.” For all analyses, 
“psychiatric medication” was also included as confounding 
variable. All variables were examined to ensure that statistical 
assumptions were met.
Comorbid Substance Use Disorders and  
Plasma Chemokine Concentrations
Plasma concentrations of chemokines were not found to be 
affected by any of the variables evaluated, with the exception of 
CCL11. We observed no main effect of “comorbid substance use 
disorders” on CCL11 concentrations (Figure 3A) but there was 
a main effect of “sex” [F(1,79) = 11.132, p < 0.001] with no interac-
tion between both factors (Figure  3B). As expected, “age” was 
also significantly related to CCL11 concentrations [F(1,79) = 5.572, 
p = 0.021].
Comorbid Mental Disorders and Plasma Chemokine 
Concentrations
Regarding the diagnosis of comorbid mental disorders, we 
observed significant effects on CCL11 concentrations. Thus, 
Table 5 | Prevalence of mental disorders in abstinent alcohol use disorders patients with comorbid mental disorders grouped according to sex.
Mental disorders alcohol subgroup with comorbid mental disorders
Male (N = 40) Female (N = 21) Total (N = 61)
Mood disorders No 14 (35.0) 5 (23.8) 19 (31.1)
Yes 26 (65.0) 16 (76.2) 42 (68.9)
Primary 10 9 19
Alcohol-induced 17 11 28
Both 1 4 5
Major depression 26 16 42
Dysthymia 0 1 1
Mania 3 0 3
Hipomania 1 0 1
Cyclothymia 0 0 0
Anxiety disorders No 30 (75.0) 16 (76.2) 46 (75.4)
Yes 10 (25.0) 5 (23.8) 15 (24.6)
Primary 6 5 11
Alcohol-induced 5 0 5
Both 1 0 1
Specific phobia 0 0 0
Social phobia 1 0 1
Panic disorder/agoraphobia 6 2 8
Generalized anxiety disorder 2 1 3
Obsessive–compulsive disorder 0 0 0
Posttraumatic stress disorder 2 2 4
Psychotic disorders No 36 (90.0) 19 (90.5) 55 (90.2)
Yes 4 (10.0) 2 (9.5) 6 (9.8)
Primary 1 1 2
Alcohol-induced 3 1 4
Both 0 0 0
Schizoaffective disorder 0 0 0
Brief psychotic disorder 1 0 1
Delusional disorder 0 0 0
Mood disorder with psychotic feature 3 2 5
Psychosis due to a medical condition 0 0 0
Psychosis not otherwise specified 1 0 1
Eating disorders No 40 (100.0) 19 (90.5) 59 (96.7)
Yes 0 (0.0) 2 (9.5) 2 (3.3)
Anorexia nervosa 0 0 0
Bulimia nervosa 0 2 2
Binge eating disorder 0 0 0
Personality disorders No 26 (65.0) 14 (52.4) 40 (66.7)
Yes 14 (35.0) 7 (47.6) 21 (33.3)
Borderline disorder 8 7 15
Antisocial disorder 7 0 7
ADHD No 21 (52.5) 18 (85.7) 39 (63.9)
Yes 19 (47.5) 3 (14.3) 22 (36.1)
ADHD, attention deficit hyperactivity disorder.
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statistical analysis revealed a significant main effect of “comorbid 
mental disorders” [F(1,79) = 7.559, p = 0.007] on CCL11 concen-
trations as shown in Figure  3C, and patients diagnosed with 
comorbid mental disorders had decreased CCL11 concentrations 
relative to non-comorbid patients [36.79 (95% CI = 33.59–39.99) 
pg/mL and 44.58 (95% CI = 39.46–49.70) pg/mL, respectively]. 
Again, there was a significant effect of “sex” [F(1,79)  =  6.524, 
p = 0.013] on CCL11 concentrations (Figure 3D) and the covari-
ate “age” was also related to CCL11 concentrations [F(1,79) = 6.752, 
p = 0.011].
comorbid Mental Disorders and Plasma 
ccl11 concentrations in abstinent  
aUD Patients
As a continuation of the effects of comorbid mental disorders 
on CCL11 expression, we evaluated the contribution of the most 
prevalent mental disorders.
We analyzed the effects of these psychiatric disorders on 
CCL11 including “sex” and controlling for “age” and “psychiatric 
medication” (Figure 3E). Thus, a two-way ANCOVA revealed 
FigUre 3 | Plasma concentrations of ccl11 (eotaxin-1) in abstinent alcohol use disorders patients according to psychiatric comorbidity.  
(a) CCL11 (eotaxin-1) concentrations according to “comorbid substance use disorders”; (b) CCL11 (eotaxin-1) concentrations according to “comorbid substance 
use disorders” and “sex”; (c) CCL11 (eotaxin-1) concentrations according to “comorbid mental disorders”; (D) CCL11 (eotaxin-1) concentrations according to 
“comorbid mental disorders” and “sex”; and (e) CCL11 (eotaxin-1) concentrations according to mood disorders, anxiety, psychotic disorders, personality disorders, 
and ADHD. Bars are estimated marginal means and 95% CI (picograms per milliliter). Data were analyzed by two-way analysis of covariance and *p < 0.05, 
**p < 0.01, and ***p < 0.001 denote significant main effect of factors.
11
García-Marchena et al. Chemokines and Alcohol
Frontiers in Psychiatry | www.frontiersin.org January 2017 | Volume 7 | Article 214
that CCL11 concentrations were significantly affected by 
“mood disorders” [F(1,79) = 4.627, p = 0.034] and the estimated 
CCL11 mean was lower in patients diagnosed with mood 
disorders than in patients with no mood disorders [35.92 (95% 
CI = 32.15–39.68) pg/mL and 41.28 (95% CI = 37.34–45.23) pg/
mL, respectively].
FigUre 4 | Plasma concentrations of cXcl12 [stromal cell-derived factor-1 (sDF-1)], cX3cl1 (fractalkine), and ccl11 (eotaxin-1) in male Wistar rats 
exposed to ethanol and acute stress. (a) CXCL12 (SDF-1) and (b) CX3CL1 (fractalkine) concentrations were determined in rats exposed to ethanol (3 g/kg, i.g.) 
during 4 weeks or vehicle. (c) CCL11 (eotaxin-1) concentrations were determined in rats exposed to ethanol (3 g/kg, i.g.) during 4 weeks or vehicle with/without 
acute stress before ethanol exposure. Bars are means and SEM (nanograms per milliliter). CXCL12 and CX3CL1 concentrations were analyzed by Student’s t-test 
and &&p < 0.01 denotes significant differences compared to the vehicle group. CCL11 concentrations were analyzed by two-way analysis of variance (ANOVA) and 
**p < 0.01 and ***p < 0.001 denote significant main effect of “stress” and “ethanol exposure,” respectively. (D) CXCL12 (SDF-1); (e) CX3CL1 (fractalkine); and 
(F) CCL11 (eotaxin-1) concentrations were determined in rats exposed to acute ethanol (3 g/kg, i.g.) at 0, 30, 60, 120, and 240 min after ethanol exposure. Circles 
are means and SEM (nanograms per milliliter). CXCL12, CX3CL1, and CCL11 concentrations were analyzed by one-way ANOVA and *p < 0.05, **p < 0.01, and 
***p < 0.001 denote significant main effect of “time.” +p < 0.05 and ++p < 0.01 denote significant differences compared to t = 0 min. White circles are means and 
SEM (nanograms per milliliter) at t = 240 min with no ethanol exposure and concentrations were analyzed by Student’s t-test. &p < 0.05 denotes significant 
differences compared to t = 0 or 240 min with no ethanol.
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Plasma CCL11 concentrations were also affected by “anxiety” 
[F(1,79) = 4.941, p = 0.028] and the estimated marginal mean of 
CCL11 was lower in patients diagnosed with lifetime anxiety than 
in patients with no anxiety [32.71 (95% CI = 26.55–38.88) pg/mL 
and 39.86 (95% CI = 36.19–42.93) pg/mL, respectively].
Not surprisingly, the statistical analysis of the effects of these 
common mental disorders on CCL11 expression revealed a sig-
nificant main effect of “sex” with no interaction. Therefore, female 
patients displayed lower concentrations than male patients (for 
clarity, statistics related to “sex” were not included to prevent 
repetitive outputs). Therefore, female abstinent patients diag-
nosed with lifetime anxiety (N = 5) and/or displayed the lowest 
concentrations of CCL11 [26.38 (95% CI = 16.47–36.29) pg/mL].
Plasma chemokine concentrations  
in rats exposed to ethanol
CXCL11, CX3CL1, and CCL12 concentrations were examined in 
Wistar rats exposed to repeated and acute ethanol. In addition to 
ethanol, CCL11 concentrations were also examined in abstinent 
rats exposed to acute stress induced by immobilization. To sim-
plify the experiments, we included only male rats at the same age.
Plasma Chemokine Concentrations  
in Rats Exposed to Repeated Ethanol
Because only CXCL12 and CX3CL1 concentrations were found to 
be altered in the plasma of abstinent AUD patients relative to the 
control group in humans, we tested whether these chemokines 
were also affected by ethanol administration in abstinent 
Wistar rats. Two weeks after the last ethanol administration 
alcohol-exposed rats had lower CXCL12 concentrations than 
vehicle-treated rats, resulting in a significant decrease [t(38) = 2.99, 
p = 0.005] (Figure 4A). However, we observed no significant dif-
ferences in plasma CX3CL1 concentrations between both groups 
(Figure 4B).
In humans, we found that the CCL11 expression was 
significantly affected by lifetime mental disorders, especially 
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mood disorders and anxiety disorders. In order to investigate 
the potential link of this chemokine to emotional behaviors, 
we investigated whether these effects on CCL11 concentrations 
were also observed in male Wistar rats exposed to acute stress 
induced by immobilization and treated with ethanol. As shown in 
Figure 4C, a two-way ANOVA revealed a main effect of “ethanol 
exposure” [F(1,73) = 27.02, p < 0.001] with higher CCL11 concen-
trations in alcohol-exposed rats compared to vehicle rats and a 
main effect of early “stress” [F(1,73) = 6.975, p < 0.01] with higher 
CCL11 concentrations in rats exposed to stress compared to rats 
without restraint. There was no interaction between both factors.
Plasma Chemokine Concentrations  
in Rats Exposed to Acute Ethanol
To study the impact of acute ethanol on these chemokines, 
another set of male Wistar rats were treated with ethanol (i.g.) 
and CXCL12, CX3CL1, and CCL11 concentrations were deter-
mined in the plasma during 4 h at different times (0, 30, 60, 120, 
and 240 min). Data were analyzed using one-way ANOVA with 
post hoc comparisons.
As shown in Figure 4D, there was a significant main effect 
of “time” on CXCL12 concentrations across the experimental 
groups [F(4,67) =  3.871, p =  0.007] but the post  hoc tests only 
found a significant decrease in CXCL12 at 240 min after receiv-
ing ethanol compared to the t = 0 min (p < 0.05). An additional 
group of rats with no ethanol exposure was examined at 240 min 
after beginning the experiment and this group displayed higher 
CXCL12 concentrations than the t = 0 min [t(20) = 2.22, p = 0.038]. 
Consequently, ethanol-treated rats showed lower CXCL12 
concentrations relative to naive rats at 240  min [t(20) =  5.17, 
p < 0.001].
Regarding CX3CL1, one-way ANOVA revealed a significant 
main effect of “time” in the subgroups [F(4,65) = 4.166, p < 0.001] 
(Figure  4E). In fact, CX3CL1 concentrations were significantly 
increased at 120  min after ethanol exposure compared to the 
t = 0 min (p < 0.05). In this case, we found no differences in the 
CX3CL1 expression when naïve groups at 0 and 240  min were 
compared. Furthermore, ethanol-treated rats and naïve rats did 
not differ in CX3CL1 concentrations at 240 min.
Similar to previous analyses, there were significant differences 
in the CCL11 expression among groups according to “time” 
after ethanol exposure [F(4,65) =  2.950, p =  0.027] (Figure  4F). 
The post  hoc tests indicated a significant increase in CCL11 
concentrations at 60 min after receiving ethanol relative to rats 
at t = 0 min (p < 0.01). Regarding the naïve groups, rats with no 
ethanol exposure showed no differences in CCL11 at t = 0 and 
240 min. There were also no differences in CCL11 concentrations 
when ethanol-treated and naïve rats were compared at 240 min.
DiscUssiOn
While the association of immune signaling and psychiatric 
disorders is widely investigated, its association with addiction 
is still a field under exploration. We lack essential information 
concerning how immune signaling in the brain contributes to 
the neuroadaptations imposed by chronic substance use. This is 
especially relevant in the case of alcohol that can directly activate 
neuroimmune processes (26). In the present study, we measured 
plasma chemokines in a well-phenotyped cohort of subjects with 
AUD in abstinence treated in an outpatient setting. This cohort 
was characterized for the high presence of psychiatric comorbid-
ity although we observed sex differences in the prevalence of 
comorbid substance use disorders and mental disorders. The 
main findings are as follows: (i) abstinent AUD patients had lower 
concentrations of CXCL12 and CX3CL1 compared to control 
subjects whereas CCL11 concentrations were strongly decreased 
in female AUD patients; (ii) CXCL8 concentrations were elevated 
in patients with cirrhosis, steatosis, or pancreatitis, particularly 
in female AUD patients, and there was a positive correlation to 
AST/GOT and GGT; (iii) CCL11 concentrations were found to 
be decreased in abstinent AUD patients with comorbid mental 
disorders (i.e., mood and anxiety disorders); (iv) there was a 
strong and permanent effect of sex and age on plasma CCL11 
concentrations in the alcohol group throughout the present 
study; (v) studies conducted in male rats exposed to repeated 
ethanol revealed similar changes in plasma CXCL12 concentra-
tions than those observed in humans during abstinence during 
abstinence and acute ethanol exposure also induced a decrease 
in CXCL12; and (vi) rats exposed to repeated ethanol and early 
stress (restraint) displayed changes in CCL11 concentrations, 
although the changes were opposite to those observed in humans.
abstinent aUD Patients have altered 
cXcl12/sDF-1 and cX3cl1/Fractalkine 
concentrations in the Plasma
Patients with a history of AUD displayed lower plasma concentra-
tions of CXCL12 and CX3CL1 relative to control subjects with no 
pathological use of substances or substance use disorders. Various 
studies have reported an association between both chemokines 
and abused drugs, mainly with cocaine. Recently, our group has 
reported a decrease in the plasma CXCL12 concentrations and 
a positive correlation between CX3CL1 concentrations and the 
cocaine symptom severity in abstinent cocaine-addicted subjects 
from outpatient setting (6, 21). In agreement with these clinical 
data, changes in the plasma concentrations of both chemokines 
have been observed in mice exposed to cocaine (21). However, 
another study in chronic cocaine users showed increased 
CXCL12 concentrations in the moment of admission for treat-
ment, although they were decreased after 1  month of cocaine 
withdrawal (27).
Unlike cocaine, there are scarce exploratory studies examining 
the circulating concentrations of CXCL12 after alcohol exposure. 
In fact, these studies conducted in humans (28) and mice (29) 
have reported high circulating concentrations of CXCL12 after 
moderate alcohol consumption. By contrast, here we found 
low concentrations of CXCL12 in AUD patients but also in rats 
exposed to repeated ethanol after 1 week of abstinence. Moreover, 
rats treated with acute ethanol displayed a decrease in CXCL12 
levels after 4 h, which is congruent with the data from repeated 
experiments. Regarding plasma CX3CL1, most studies on the 
effects of alcohol are focused on the CNS (30, 31) and pancreas 
(32, 33) but a recent study has reported elevated concentrations 
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of CX3CL1 in the serum of mice treated chronically (5 months) 
with ethanol (26), which is in opposition to our data in AUD 
patients but compatible with our preclinical data since ethanol-
treated rats had higher plasma CX3CL1 concentrations, especially 
in rats acutely treated. However, it is important to indicate that 
species, doses and intensity of the exposure were not comparable 
in between these studies and that further research is needed to 
understand the time-course of the changes in chemokines in 
plasma after acute and chronic alcohol exposure.
Therefore, although increased circulating levels of CXCL12 
and CX3CL1 after alcohol exposure are opposed to the present 
data, there are marked differences regarding the time of the last 
alcohol exposure (abstinence) and the AUD severity in the clini-
cal studies. Our study has been performed in patients diagnosed 
with AUD in a prolonged abstinence (about 9  months) and a 
history of heavy alcohol consumption, whereas the above cited 
studies in humans were performed in high cardiovascular risk 
patients reporting moderate alcohol consumption. This discrep-
ancy might indicate that both chemokines fluctuate regarding the 
duration of abstinence and intensity of alcohol use.
In addition to CXCL12 and CX3CL1, differences in CCL11 
concentrations were found between men and women but only 
in the alcohol group, which indicated the presence of a sexual 
dimorphism in the circulating CCL11 concentrations in response 
to a history of pathological alcohol exposure and/or AUD. 
By contrast, we observed differences in the expression of this 
chemokine in male rats after ethanol exposure. Thus, we found 
increased levels of CCL11 in rats treated with acute and repeated 
ethanol compared to control rats.
age and sex Differences influence  
ccl3/MiP-1α and ccl11/eotaxin-1 
concentrations in the Plasma
Age and sex are critical variables in the expression of inflam-
matory signals (34–36) and for this reason we have included 
both independent variables in the statistical analysis. Here, we 
show that CCL3 and especially CCL11 were affected by these 
physiological variables. Regarding CCL3, this is the first time 
that sex differences are showed in the circulating expression of 
this chemokine. By contrast, a growing number of clinical stud-
ies have described the association of CCL11 with age and sex 
(37, 38). For example, Targowski and colleagues reported that 
healthy young subjects (25–34 years) had lower serum levels of 
CCL11 than older participants (35–55 years). They also showed 
that there were sex differences with decreased CCL11 concentra-
tions in women (37). Similarly, another study in healthy subjects 
(40–80 years) demonstrated that the serum levels of CCL11 were 
gradually increased with age but sex differences were not found, 
suggesting that sex differences might be abolished with increasing 
age (38). Our results are in accordance with these studies because 
we found a significant effect of age on CCL11 concentrations 
that resulted in a positive correlation, particularly in the control 
group. As previously mentioned, we observed no differences in 
CCL11 concentrations in male and female controls but a clear 
decrease in the expression of this chemokine was found in female 
compared to male AUD patients. Therefore, alcohol abuse and/
or dependence could induce changes in CCL11 concentrations 
interfering in the expected effects of age and emphasizing sex 
differences.
liver and Pancreas Diseases influence 
cXcl8 concentrations in the Plasma of 
abstinent aUD Patients
The influence of variables such as the AUD severity, length of 
abstinence, and diagnosis of diseases in accessory organs in 
chemokines was evaluated in the alcohol group. Previously, 
we have reported an association between plasma concentra-
tions of CXCL12 and CX3CL1 and cocaine symptom severity 
in abstinent cocaine addicts (6) but none of these chemokines 
were affected by AUD severity. In fact, despite CXCL12 and 
CX3CL1 concentrations were found to be decreased in the 
alcohol group, none of the alcohol use-related variables had 
a significant effect. However, alcohol-induced diseases in 
accessory organs influenced strongly the plasma expression of 
CXCL8. Thus, the diagnosis of cirrhosis, hepatitis, or pancrea-
titis that reached about a 24% of AUD patients was associated 
with elevated CXCL8 concentrations. In line with these data, 
clinical and preclinical studies have showed that increased 
concentrations of CXCL8 are involved in the pathogenesis of 
alcoholic liver and pancreas diseases (39, 40). Predictably, there 
was an increase of plasma levels of markers linked to alcoholic 
liver and pancreas damage in patients diagnosed with cirrhosis, 
hepatitis, and/or pancreatitis. Intriguingly, when we studied 
the association of these markers with chemokines in our 
sample, we found only a strong association of AST/GOT and 
GGT levels with CXCL8 concentrations. Therefore, the present 
study confirms the role of CXCL8 as a putative indicator of 
pancreatitis and liver disease.
Psychiatric comorbidity influences 
ccl11/eotaxin-1 concentrations in the 
Plasma of abstinent aUD Patients
Most studies on CCL11 are associated with allergy and asthma 
because this chemokine has been identified as a potential 
biomarker for the diagnosis and assessment of asthma severity 
and control (41) but there are no studies on the role of CCL11 
in addictive disorders. In our exploratory approach, we studied 
the potential effect of the presence of psychiatric comorbidity 
on chemokine concentrations on account of the high rate of 
prevalence in the alcohol group. As expected, abstinent AUD 
patients showed an elevated psychiatric comorbidity and about 
40% of patients were diagnosed with abuse and/or depend-
ence of other psychoactive substances as well as other mental 
disorders.
While a pathological use of other substance(s) and alcohol had 
no effects on any of the chemokines evaluated, the diagnosis of 
mental disorders had a primary effect on the plasma expression 
of CCL11. Several studies have reported the association between 
blood levels of CCL11 and psychiatric disorders, for example in 
schizophrenia (42), bipolar disorders (43, 44), major depression 
(45), and psychopathologies with suicidal ideation (45), but 
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there are no studies in a context of substance use disorders. Our 
data revealed a decreased expression of CCL11 concentrations in 
abstinent AUD patients diagnosed with non-substance mental 
disorders. Remarkably, this decrease was observed to be more 
enhanced in women with mental disorders who displayed lower 
prevalence of comorbid substance use disorders than men. After 
evaluating common psychiatric disorders separately, mood 
disorders and anxiety confirmed their association with lower 
concentrations of CCL11 in abstinent AUD patients. Evidence 
points to a strong association between high concentrations in 
blood CCL11 and the decline in neurogenesis and cognitive 
impairments (46), and this fact is observed in aged subjects. 
Accordingly, we have described a clear association between 
CCL11 concentrations and age but the decreased concentrations 
observed in comorbid AUD patients are opposite to previous 
studies in psychiatric disorders, which reported increased 
concentrations of CCL11 in the serum of patients (7, 42–45). 
However, none of the referred studies were performed in the 
context of substance use disorders and several differences are 
found with respect to the present study.
Interestingly, a clinical study in young adults from general 
population by Magalhaes and colleagues reported no effects 
of the diagnosis of substance use disorders as predictor of 
CCL11 concentrations although both bipolar and depression 
disorders and sex influenced significantly the expression of this 
chemokine (7), which is in agreement with the present study in 
AUD patients. However, the presence of both bipolar and major 
depression disorders was associated with higher concentrations 
of CCL11 in contrast to our clinical data. Regarding the associa-
tion between anxiety disorders and CCL11 concentrations, we 
found no studies in addicted subjects and only a study in anxious 
subjects with obsessive–compulsive disorder has examined this 
chemokine in the plasma but no changes were reported (47). 
Nevertheless, in the present study we found differences between 
human and rat. Thus, while anxious AUD patients had lower 
CCL11 concentrations, ethanol-exposed rats with a previous 
stress episode by restraint had higher levels of CCL11 in the 
plasma. It is important to note that all patients were receiving 
treatment at the time of sampling and the impact that both the 
pharmacological therapy and the psychological interventions 
may have on plasma CCL11 concentrations cannot be assessed 
taking into consideration the cross-sectional design of the pre-
sent study. Indeed, this potential impact will be studied in future 
longitudinal studies.
limitations and Future Perspectives
The present findings support the importance of monitor-
ing chemokines in the context of complex disorders such as 
substance use disorders including AUD. We are aware of the 
limitations of this exploratory study, which need to be borne 
in mind in interpreting the data. First, the validity of the results 
presented here needs to be assessed in a larger sample of patients 
and include psychiatric patients with no history of substance use 
disorders or pathological use of substances. Second, additional 
studies to determine plasma chemokines in active alcohol users 
are necessary to test the effect of alcohol on these inflamma-
tory signals considering the differences and effects observed in 
preclinical data with rats. Third, the impact of sex differences 
in both the prevalence of psychiatric disorders and plasma 
concentrations of chemokines (e.g., CCL3 and CCL11) requires 
a higher effort on recruiting female participants and a better 
clinical characterization (stage of menstrual cycle, levels of lute-
inizing hormone, follicle-stimulating hormone, and estrogen…) 
because the average age of the women seeking treatment for 
alcohol problems usually belongs to the menopause transition 
years. In fact, the lack of data in female rats exposed to ethanol 
represents a limitation that will need to be addressed in future 
investigations.
Although CCL11 could be proposed as a potential indicator of 
psychiatric comorbidity in abstinent subjects with AUD, there are 
no data about other drugs of abuse. Further clinical and preclini-
cal research is necessary to elucidate the role of chemokines and 
sex in the etiology of alcoholism and psychiatric disorders.
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